menu

Exploring a Case in vHABP Care From Physician & Patient Perspectives

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Exploring a Case in vHABP Care From Physician & Patient Perspectives

3 chapters
Play All
Program Information
Chapters
Recommended

Program Information

Chapter 1
ReachMD Healthcare Image
RestartResume

Many challenges are faced when treating ventilated hospital-acquired bacterial pneumonia, but these insights from a physician and patient can help.

Please See

Indication and Important Safety Information

  • INDICATION and IMPORTANT SAFETY INFORMATION

    Indication
    ZERBAXA® (ceftolozane and tazobactam) for injection (1.5 g) is indicated for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible Gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Serratia marcescens.

    Usage
    To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

    Important Safety Information

    • Patients with renal impairment: Dose adjustment is required for patients with CrCl 50 mL/min or less. All doses of ZERBAXA are administered over 1 hour. Monitor CrCl at least daily in patients with changing renal function and adjust the dose of ZERBAXA accordingly.
    • Hypersensitivity: ZERBAXA is contraindicated in patients with known serious hypersensitivity to the components of ZERBAXA (ceftolozane/tazobactam), piperacillin/tazobactam, or other members of the beta-lactam class. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterials. Before initiating therapy with ZERBAXA, make careful inquiry about previous hypersensitivity reactions to cephalosporins, penicillins, or other beta-lactams. If an anaphylactic reaction to ZERBAXA occurs, discontinue use and institute appropriate therapy.
    • Clostridioides difficile-associated diarrhea (CDAD), ranging from mild diarrhea to fatal colitis, has been reported with nearly all systemic antibacterial agents, including ZERBAXA. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents. If CDAD is confirmed, antibacterial use not directed against C. difficile should be discontinued, if possible.
    • Development of drug-resistant bacteria: Prescribing ZERBAXA in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and risks the development of drug-resistant bacteria.
    • Adverse reactions: The most common adverse reactions occurring in ≥5% of patients in the HABP/VABP trial were hepatic transaminase increased (11.9%), renal impairment/renal failure (8.9%), and diarrhea (6.4%).

    Before prescribing ZERBAXA, please read the accompanying Prescribing Information.

  • Overview

    Ventilated hospital-acquired bacterial pneumonia (vHABP) is bacterial pneumonia that occurs 48 hours or more after admission, which was not incubating at the time of admission, where that patient subsequently experiences acute respiratory failure and requires ventilation. Since there are a number of key challenges faced when treating these critically ill patients, Dr. Joshua Rosenberg is here to share a patient case in vHABP care demonstrating common challenges encountered and the importance of selecting a timely and appropriate antibiotic therapy.
    Ventilated hospital-acquired bacterial pneumonia (vHABP) is bacterial pneumonia that occurs 48 hours or more after admission, which was not incubating at the time of admission, where that patient subsequently experiences acute respiratory failure and requires ventilation. Since there are a number of key challenges faced when treating these critically ill patients, Dr. Joshua Rosenberg is here to share a patient case in vHABP care demonstrating common challenges encountered and the importance of selecting a timely and appropriate antibiotic therapy.
Schedule26 Jan 2022
Webpack App